Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTAU182CXC

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
     1
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
      2
                 "Ask CAS" for self-help around the clock
NEWS
        SEP 09
                CA/CAplus records now contain indexing from 1907 to the
                 present
NEWS
        AUG 05
                New pricing for EUROPATFULL and PCTFULL effective
                 August 1, 2003
NEWS
     5
        AUG 13
                Field Availability (/FA) field enhanced in BEILSTEIN
NEWS
     6
        AUG 18
                Data available for download as a PDF in RDISCLOSURE
NEWS
     7
        AUG 18
                Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18
                FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                 Truncation
NEWS 9 AUG 18
                Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
             MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
             AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS
             STN Operating Hours Plus Help Desk Availability
NEWS INTER
             General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
             Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:47:06 ON 07 DEC 2003

=> b ca COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 19:47:15 ON 07 DEC 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Dec 2003 VOL 139 ISS 24 FILE LAST UPDATED: 4 Dec 2003 (20031204/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (guillian(w)barre(w)syndrome) or (motor(w)neuropathy) or (peripheral (w) neuropathy) or (autoimmune (w) neuropathy) 4 GUILLIAN 959 BARRE 80839 SYNDROME 4 GUILLIAN (W) BARRE (W) SYNDROME 69515 MOTOR 7932 NEUROPATHY 160 MOTOR (W) NEUROPATHY 152253 PERIPHERAL 7932 NEUROPATHY 1891 PERIPHERAL (W) NEUROPATHY 29909 AUTOIMMUNE 7932 NEUROPATHY 37 AUTOIMMUNE (W) NEUROPATHY 1.1 2057 (GUILLIAN(W)BARRE(W)SYNDROME) OR (MOTOR(W)NEUROPATHY) OR (PERIPH ERAL (W) NEUROPATHY) OR (AUTOIMMUNE (W) NEUROPATHY) => s l1 and ganglioside? 11836 GANGLIOSIDE? L296 L1 AND GANGLIOSIDE? => s 12 and antibod? 379987 ANTIBOD? L3 76 L2 AND ANTIBOD? => s 13 and (surface(w)plasmon(w)resonance) 1766805 SURFACE 15074 PLASMON

=> d all

L4 ANSWER 1 OF 1 CA COPYRIGHT 2003 ACS on STN

4557 SURFACE (W) PLASMON (W) RESONANCE

1 L3 AND (SURFACE (W) PLASMON (W) RESONANCE)

AN 136:18927 CA

L4

ED Entered STN: 03 Jan 2002

431987 RESONANCE

TI A surface plasmon resonance biosensor assay for measurement of anti-GM1 antibodies in neuropathy

AU Alaedini, Armin; Latov, Norman

CS Department of Neurology, Columbia University, New York, NY, 10032, USA

SO Neurology (2001), 56(7), 855-860 CODEN: NEURAI; ISSN: 0028-3878

```
PB
     Lippincott Williams & Wilkins
DT
     Journal
LA
     English
CC
     15-1 (Immunochemistry)
     Section cross-reference(s): 9
     Objective is to develop a rapid assay for the detection and measurement of
     anti-GM1 ganglioside antibodies in patients with
     neuropathy, using a surface plasmon resonance
     -based biosensor. Elevated levels of anti-GM1 ganglioside
     antibodies are obsd. in patients with acute and chronic motor
     neuropathies. Assays for detecting anti-GM1 antibodies in serum
     are increasingly being used to help the physician in the evaluation of
     these patients. Antigens were immobilized by adsorption of GM1 (active)
     and GM2 (control) gangliosides onto a dextran-based sensor chip
     which is in contact with a flow cell carrying the sample. Interaction of
     specific antibodies directed against GM1 with the
     ganglioside-coated sensor chip caused a change in refractive index
     at the surface of the chip, which was detected by an optical sensor, using
     the phenomenon of surface plasmon resonance.
     Sera from patients and healthy individuals were analyzed by the new assay
     and results were compared with those from ELISA. Anti-GM1
     antibody isotype was identified by using a secondary
     antibody. The binding of anti-GM1 antibodies to the
     immobilized GM1 was obsd. in real time after ref. subtraction of the
     response from GM2 control. The response was proportional to
     antibody concn. The assay exhibited high specificity for sera
     from patients with multi-focal motor neuropathy and
     Guillain-Barre syndrome with antibodies against GM1.
     surface plasmon resonance biosensor assay
     offers a rapid system for directly measuring antibody levels in
     serum without the use of any labels, while comparing favorably with the
     ELISA system in sensitivity and specificity.
ST
     biosensor immunoassay ganglioside GM1 antibody
     neuropathy
IT
     Immunoglobulins
     RL: ANT (Analyte); ANST (Analytical study)
        (G; surface plasmon resonance biosensor
        assay for anti-GM1 antibody measurement in neuropathy)
IT
     Nervous system, disease
        (Guillain-Barre syndrome; surface plasmon
        resonance biosensor assay for anti-GM1 antibody
        measurement in)
IT
     Immunoglobulins
     RL: ANT (Analyte); ANST (Analytical study)
        (M; surface plasmon resonance biosensor
        assay for anti-GM1 antibody measurement in neuropathy)
IT
     Adsorption
        (immunoadsorption; adsorption of GM1 gangliosides onto a
        dextran-based sensor ship)
IT
     Nerve, disease
        (neuropathy; surface plasmon resonance
        biosensor assay for anti-GM1 antibody measurement in
        neuropathy)
IT
     Molecular association
        (of ganglioside GM1 with antibodies)
IT
     Immobilization, molecular
        (protein; adsorption of GM1 gangliosides onto a dextran-based
        sensor ship)
IT
     Biosensors
     Immunoassay
        (surface plasmon resonance biosensor
        assay for anti-GM1 antibody measurement in neuropathy)
IT
     37758-47-7, Ganglioside GM1
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (surface plasmon resonance biosensor
```

assay for anti-GM1 antibody measurement in neuropathy) THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD RE.CNT 15 RE (1) Asbury, A; Ann Neurol 1990, V27, PS21 (2) Asbury, A; J Child Neurol 2000, V15, P183 MEDLINE (3) Briani, C; Neuromuscul Disord 1996, V6, P311 MEDLINE (4) Carpo, M; Neurology 1999, V53, P2206 MEDLINE (5) Fagerstam, L; J Chromatogr 1992, V597, P397 MEDLINE (6) Holloway, R; Neurology 1999, V53, P1905 MEDLINE(7) Kinsella, L; Neurology 1994, V44, P1278 MEDLINE (8) Kissel, J; Semin Neurol 1998, V18, P83 MEDLINE (9) Malmqvist, M; Biochem Soc Trans 1999, V27, P335 CA (10) Marcus, D; J Neuroimmunol 1989, V25, P255 MEDLINE (11) Pestronk, A; Ann Neurol 1988, V24, P73 MEDLINE (12) Pestronk, A; Muscle Nerve 1991, V14, P927 MEDLINE (13) Pestronk, A; Neurology 2000, V54, P2353 MEDLINE (14) Sadiq, S; Neurology 1990, V40, P1067 MEDLINE (15) van Den Berg, L; Muscle Nerve 1996, V19, P637 MEDLINE => b medline COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 27.15 27.36 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -0.62 -0.62 FILE 'MEDLINE' ENTERED AT 19:49:35 ON 07 DEC 2003 FILE LAST UPDATED: 2 DEC 2003 (20031202/UP). FILE COVERS 1958 TO DATE. On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details. MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See http://www.nlm.nih.gov/mesh/changes2003.html for a description on changes. This file contains CAS Registry Numbers for easy and accurate substance identification. => d his (FILE 'HOME' ENTERED AT 19:47:06 ON 07 DEC 2003) FILE 'CA' ENTERED AT 19:47:15 ON 07 DEC 2003 2057 S (GUILLIAN (W) BARRE (W) SYNDROME) OR (MOTOR (W) NEUROPATHY) OR (PER L1L296 S L1 AND GANGLIOSIDE? 76 S L2 AND ANTIBOD? L3L41 S L3 AND (SURFACE (W) PLASMON (W) RESONANCE) FILE 'MEDLINE' ENTERED AT 19:49:35 ON 07 DEC 2003 => s 14 46 GUILLIAN 4333 BARRE 516954 SYNDROME 38 GUILLIAN (W) BARRE (W) SYNDROME 158727 MOTOR 26087 NEUROPATHY 732 MOTOR (W) NEUROPATHY 272961 PERIPHERAL 26087 NEUROPATHY 6111 PERIPHERAL (W) NEUROPATHY

65803 AUTOIMMUNE 26087 NEUROPATHY 25 AUTOIMMUNE (W) NEUROPATHY 11876 GANGLIOSIDE? 645391 ANTIBOD? 394494 SURFACE 2780 PLASMON 237628 RESONANCE 2605 SURFACE (W) PLASMON (W) RESONANCE L5 1 L3 AND (SURFACE (W) PLASMON (W) RESONANCE) => d ti L5 ANSWER 1 OF 1 MEDLINE on STN TIA surface plasmon resonance biosensor assay for measurement of anti-GM(1) antibodies in neuropathy. => b uspatfull COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.38 27.74 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -0.62 FILE 'USPATFULL' ENTERED AT 19:50:01 ON 07 DEC 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE COVERS 1971 TO PATENT PUBLICATION DATE: 4 Dec 2003 (20031204/PD) FILE LAST UPDATED: 4 Dec 2003 (20031204/ED) HIGHEST GRANTED PATENT NUMBER: US6658663 HIGHEST APPLICATION PUBLICATION NUMBER: US2003226186 CA INDEXING IS CURRENT THROUGH 4 Dec 2003 (20031204/UPCA) ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 4 Dec 2003 (20031204/PD) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2003 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2003 >>> USPAT2 is now available. USPATFULL contains full text of the original, i.e., the earliest published granted patents or >>> applications. USPAT2 contains full text of the latest US <<< publications, starting in 2001, for the inventions covered in >>> USPATFULL. A USPATFULL record contains not only the original >>> <<< >>> published document but also a list of any subsequent <<< publications. The publication number, patent kind code, and <<< publication date for all the US publications for an invention <<< are displayed in the PI (Patent Information) field of USPATFULL >>> records and may be searched in standard search fields, e.g., /PN, <<< /PK, etc. >>> >>> USPATFULL and USPAT2 can be accessed and searched together <<< >>> through the new cluster USPATALL. Type FILE USPATALL to <<< >>> enter this cluster. <<< >>> <<< >>> Use USPATALL when searching terms such as patent assignees, <<< classifications, or claims, that may potentially change from <<< >>> the earliest to the latest publication.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14

```
44559 SYNDROME
            74 GUILLIAN (W) BARRE (W) SYNDROME
        601662 MOTOR
          6201 NEUROPATHY
            66 MOTOR (W) NEUROPATHY
        479312 PERIPHERAL
          6201 NEUROPATHY
          2708 PERIPHERAL (W) NEUROPATHY
         19062 AUTOIMMUNE
          6201 NEUROPATHY
             4 AUTOIMMUNE (W) NEUROPATHY
          2987 GANGLIOSIDE?
         93323 ANTIBOD?
       2135126 SURFACE
          3783 PLASMON
        108992 RESONANCE
          3165 SURFACE (W) PLASMON (W) RESONANCE
L6
            26 L3 AND (SURFACE (W) PLASMON (W) RESONANCE)
=> d ti 1-26
     ANSWER 1 OF 26 USPATFULL on STN
       Human cDNAs and proteins and uses thereof
TI
L6
     ANSWER 2 OF 26 USPATFULL on STN
TI
       Individualization of therapy with antiviral agents
L6
     ANSWER 3 OF 26 USPATFULL on STN
TI
       Use of metabolic phenotyping in individualized treatment with amonafide
L6
     ANSWER 4 OF 26 USPATFULL on STN
TI
       Individualization of therapy with antibiotic agents
L6
     ANSWER 5 OF 26 USPATFULL on STN
TI
       Individualization of therapy with antihistamines
L6
     ANSWER 6 OF 26 USPATFULL on STN
       Individualization of therapy with anxiolitics
TI
L6
     ANSWER 7 OF 26 USPATFULL on STN
       Human cDNAs and proteins and uses thereof
TI
     ANSWER 8 OF 26 USPATFULL on STN
L6
TI
       Individualization of therapy with antipsychotics
     ANSWER 9 OF 26 USPATFULL on STN
L6
ΤI
       Human cDNAs and proteins and uses thereof
     ANSWER 10 OF 26 USPATFULL on STN
L6
TI
       Human cDNAs and proteins and uses thereof
L6
    ANSWER 11 OF 26 USPATFULL on STN
ΤI
       Use of metabolic phenotyping in individualized treatment with amonafide
    ANSWER 12 OF 26 USPATFULL on STN
L6
TI
       Individualization of therapy with Alzheimer's disease agents
     ANSWER 13 OF 26 USPATFULL on STN
L6
TI
       Individualization of therapy with antiarrhythmics
L6
    ANSWER 14 OF 26 USPATFULL on STN
TI
       Individualization of therapy with antineoplastic agents
L6
     ANSWER 15 OF 26 USPATFULL on STN
TI
      Human cDNAs and proteins and uses thereof
```

L6	ANSWER 16 OF 26 USPATFULL on STN		
TI	Human cDNAs and proteins and uses thereof		
L6 TI			
L6	ANSWER 18 OF 26 USPATFULL on STN		
TI	Individualization of therapy with analgesics		
L6	ANSWER 19 OF 26 USPATFULL on STN		
TI	Individualization of therapy with erectile dysfunction agents		
L6 TI	ANSWER 20 OF 26 USPATFULL on STN Individualization of therapy with antidepressants		
L6	ANSWER 21 OF 26 USPATFULL on STN		
TI	Individualization of therapy with immunosuppressants		
L6	ANSWER 22 OF 26 USPATFULL on STN		
TI	Individualization of therapy with hyperlipidemia agents		
L6 TI	ANSWER 23 OF 26 USPATFULL on STN Individualization of therapy with gastroesophageal reflux disease agents		
L6	ANSWER 24 OF 26 USPATFULL on STN		
TI	Human cDNAs and proteins and uses thereof		
L6 TI	ANSWER 25 OF 26 USPATFULL on STN Human cDNAs and proteins and uses thereof		
L6 TI	ANSWER 26 OF 26 USPATFULL on STN Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy		
=> logoff y COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION			

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 1.27	SESSION 29.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY 0.00	SESSION -0.62

STN INTERNATIONAL LOGOFF AT 19:50:40 ON 07 DEC 2003